SlideShare a Scribd company logo
The postantibiotic and sub-MIC
The postantibiotic and sub-MIC
effects in vitro and in vivo
effects in vitro and in vivo
Inga Odenholt, MD., Ph.D.
Department of Infectious Diseases
University hospital
Malmö
Sweden
The postantibiotic effect in vitro
The postantibiotic effect in vitro
Postantibiotic effect;
Postantibiotic effect;
PAE in vitro
PAE in vitro
Definition:
• Suppression of bacterial growth after short
exposure of organisms to antibiotics
PAE=T-C
T= The time required for the exposed culture to
increase one log10 above the count observed
immediately after drug removal
C= The corresponding time for the unexposed
control
Postantibiotic effect
9

8

7

log10 cfu/mL

2.3 h

Control

6

PAE
5

4

3
0

2

4

6

8

10

12

h

Odenholt et al. SJID, 1988
Postantibiotic effect
Postantibiotic effect
in vitro
in vitro
The PAE is dependent on:
• Type of antibiotic
• Type of bacterial species
• Concentration of the antibiotic
• Duration of exposure
• Size of the inoculum
• Growth phase of the organism
PAE against Gram-positive bacteria
Antibiotics
• Penicillins
• Cephalosporins
• Carbapenems
• Quinolones
• Proteinsythesis inhibitors

hours
1-2
1-2
1-2
1-3
3-5
PAE against Gram-negative bacteria
PAE against Gram-negative bacteria
•
•
•
•
•
•

Antibiotics
Penicillins
Cephalosporins
Carbapenems
Quinolones
Proteinsythesis inhibitors
Aminoglycosides

hours
0
0
(1)
1-3
3-8
2-4
PAE against P. aeruginosa
PAE against P. aeruginosa

•
•
•
•
•

Antibiotics
Penicillins
Cephalosporins
Carbapenems
Quinolones
Aminoglycosides

hours
0
0
1-2
1-2
2-3
The PAE at different concentrations against E. coli
8
7
6

hours

5
Rifampicin

4

Tetracykline
Cefamandole

3
2
1
0
0,5

1

2

4
xMIC

8

16

32

Craig & Gudmundsson, 1991
PAE at different exposure times against S. aureus
6

5

PAE (h)

4
Penicillin
Erythromycin

3

2

1

0
0

2

4

6

8

10

12hours
Effect on inoculum size on the PAE
120

100

Min

80
10 9 cfu/mL
10 7 cfu/mL

60

10 5 cfu/mL
10 3 cfu/mL

40

20

0
1
Ciprofloxacin

2
Tobramycin
PAE in vitro
PAE in vitro
Methods
Methods
1.

Viable counts

Methodological pitfalls
• may overestimate killing
• negative PAEs are common with ß-lactams
and gram-negatives due to forming of filaments
• similar inocula of the control and the preexposed culture are desirable
Postantibiotic effect
9

8

7

log10 cfu/mL

2.3 h

Control

6

PAE
5

4

3
0

2

4

6

8

10

12

h

Odenholt et al. SJID, 1988
PAE in vitro
PAE in vitro
Methods
Methods
2.

Optical density

Methodological pitfalls
• killing cannot be measured due to a detection limit
of 106 cfu/ml
• control curves at different inocula and viable
counts after drug removal are necessary to be
performed to ensure that PAE culture and control
are at the same inoculum
PAE in vitro
PAE in vitro
Methods
Methods
3.

ATP measurement

Methodological pitfalls

• bactericidal activity is underestimated due to dead
but intact (not lysed) bacteria still containing
intracellular ATP
• PAE is overestimated due to falsely elevated ATP
content
PAE measured with ATP
-7

log10 M bacterial ATP

-8

-9

Control
PAE

Dilution
-10

-11
0

1

2

3

4

5

6

7

8

9

h
PAE in vitro
PAE in vitro
Methods
Methods
Morphology

4.

• Phase contrast microscopy
– the time it takes for the bacteria to revert to 90%
bacilli

• Ultrastructural changes
-

the changes in structure correlates well with
the PAE measured with viable counting

5. 3H-thymidine incorporation

-correlates well with the PAE measured with
viable counting
Control related effective
Control related effective
regrowth time (CERT)
regrowth time (CERT)
CERT
CERT
• Definition
CERT=T-C
T=the time required for resumption of
logarithmic growth and increase of one
log10 to occur over the preexposed inoculum
of the test tube
Calculation of CERT with bioluminescence
3

1.3 h
2

ATP log10 M

6h

1
PAE=4,7 h

Control
PAE

0

-1

-2

h

-2

-1

0

1

2

3

4

5

6

7
Calculation of CERT using viable counts
3
1.6 h
2

log10 cfu/mL

1

0
PAE=-0.3 h
Control
PAE

-1
1.3 h

-2

-3

-4
-2

-1

0

1

2

3

4

5

6

7

h
The postantibiotic effect in vivo
The postantibiotic effect in vivo
Postantibiotic effect in vivo
Postantibiotic effect in vivo
Definition
PAE= T-C-M
• T= the time required for the counts of cfu in thighs
of treated mice to increase one log10 above the
count closest to but not less than the time M
• C= the time required for the counts of cfu in thighs
of untreated mice to increase one log10 above the
count at time zero
• M= the time serum concentration exceeds the MIC
The postantibiotic effect of gentamicin against K. pneumoniae in vivo
10
9
8

log10 cfu/mL

7
6
5
4

Control
PAE

3
T>MIC
2
1
0
-2

0

2

4

6

8

10

12

Fantin et al. JAC, 1990

14

h
PAE in vivo
PAE in vivo
• Observed in several animal models
• In vitro data are predictive of in vivo results
except that in vivo PAE are usually longer due to
the effect of sub-MICs and/or the effect of
neutrophils
• The major unexplained discordant results are for
ß-lactams and streptococci
PAE in vivo
PAE in vivo
Animal models
Animal models
•Thigh infections in mice
•Pneumonia model in mice
•Infected treads in mice
•Infected tissue cages in rabbits
•Meningitis model in rabbits
•Endocarditis model in rats
Mechanisms of PAE
Mechanisms of PAE
• β-lactam antibiotics.
At least for S. pyogenes and penicillin
it has been shown that PAE stands for
the time it takes for the bacteria to
resynthesize new PBPs
Mechanisms of PAE
Mechanisms of PAE
• Erythromycin and
clarithromycin:
50S ribosomal subunits were reduced
during 90 min and protein synthesis
during 4 h (PAE) due to prolonged
binding of the antibiotics to 50S.
Mechanisms of PAE
Mechanisms of PAE
• Aminoglycosides:
Binding of sublethal amounts of drug enough to
disrupt DNA, RNA and protein synthesis. The
time it takes to resynthesize these proteins.
With a half-life of >2.5 h, the PAE disappears,
reflecting a sufficient time for the repair
mechanism to be restored.
The postantibiotic sub-MIC
The postantibiotic sub-MIC
effect in vitro
effect in vitro
Postantibiotic sub-MIC
Postantibiotic sub-MIC
effect; PA SME
effect; PA SME
Definition
• The effect of subinhibitory antibiotic
concentrations on bacteria previously exposed to
suprainhibitory concentrations
PA SME= TPA-C
• TPA=the time it takes for the cultures previously
exposed to antibiotics and thereafter to sub-MICs
to increase by one log10 above the counts observed
immediately after washing.
• C=corresponding time for the unexposed control
PA SME of telithromycin against H. influenzae
10

9

8

log10 cfu/mL

7

6

5

PAE
0.1xMIC

4

0.2xMIC
0.3xMIC
Control

3

2

1
0

3

6

9

12

15

18

21

24

h
The postantibiotic sub-MIC
The postantibiotic sub-MIC
effect in vivo
effect in vivo
PAE PASME) in vivo of amikacin against K.
PAE (( PASME) in vivo of amikacin against K.
pneumoniae in a thigh-infection model in
pneumoniae in a thigh-infection model in
mice
mice
• Normal mice (half-life 19 min)

PAE
5.5 h

• Uremic mice (half-life 98 min)

14.6 h
The PAE and PA SME of piperacillin against S. aureus in vivo
9,00
8,50
8,00

log10 cfu/mL

7,50
7,00
Control
PAE
PA SME

6,50
6,00
5,50
Penicillinase

5,00
4,50

T>MIC

4,00

h

-2

0

2

4

6

8

10
Oshida et al. JAC, 1990
Post-MIC effect (PME)
Post-MIC effect (PME)
Post-MIC effect; PME
Post-MIC effect; PME
Definition
• The effect of sub-MICs on bacteria previously
exposed to a constant decreasing antibiotic
concentration
PME=Tpme-C
• Tpme= The time for the counts in cfu of the
exposed culture to increase one log10 above the
count observed at the MIC level
• C= the time for an unexposed control to increase
one log10
The post-MIC effect of benzylpenicillin against S. pneumoniae (PcR)
10

9

8

log10 cfu/mL

7

MIC
10mg/l
100 mg/l
Control

6

5

4

PME at 10 mg/l 12.9-2.3= 10.6

3

PME at 100 mg/l 7.5-2.3= 5.2

2

1

0

2

4 MIC

6

8

10

12

14

16

18

20

22

24 h
Mechanism of PA SME?
Mechanism of PA SME?
• The PAE of ß-lactam antibiotics seems to
represent the time necessary to synthesize
new PBPs. When bacteria in the PA-phase
are exposed to sub-MICs, most PBPs are
still inactivated and only a small amount of
the drug is needed to prolong the inhibition
of cell multiplication until a critical number
of free PBPs are once more available
Postantibiotic leucocyte
Postantibiotic leucocyte
enhancement
enhancement
Postantibiotic leucocyte
Postantibiotic leucocyte
enhancement; PALE
enhancement; PALE
• Bacteria pretreated with antibiotics for a
brief period of time show increased
susceptibility to intracellular killing and
phagocytosis
• In general, antibiotics that produce the
longest PAEs exhibit maximal PALEs
Sub-MIC effects
Sub-MIC effects
The SME of P&G kinolon against S. pneumoniae
9

8

log10 cfu/mL

7

6
Control
0.1xMIC
0.2xMIC
0.3xMIC

5

4

3

2

h

0

3

6

9

12

15

18

21

24
Sub-MIC effects; SME
Sub-MIC effects; SME
Definition
• The effect of subinhibitory antibiotic
concentrations on bacteria not previously
exposed to suprainhibitory concentrations
SME= Ts-C
•Ts=the time it takes for the cultures exposed to
sub-MICs to increase by one log10 above the counts
observed immediately after washing
•C=corresponding time for the unexposed control
Sub-MIC effects
Sub-MIC effects
• The minimum antibiotic concentrations that
produces a structural change in bacteria seen
by light or electron microscopy
• The minimum antibiotic concentration that
produces a one log10 decrease in the bacterial
population compared to the control
• Loss or change of bacterial toxins
Sub-MIC effects
Sub-MIC effects
• Loss of surface antigens resulting in
decreased adhesion
• Increased rates of phagocytic ingestion
and killing
• Increased chemotaxsis and opsonization
Mechanism of sub-MIC
Mechanism of sub-MIC
effects
effects
• SME probably tests the distribution of
antibiotic susceptibility in the bacterial
population, in which there are
subpopulations that are inhibited by
concentrations less than the MIC. The
SME would therefore represent the time
it takes for the population with the
higher MIC to become dominant
Implications
Implications
• The combined effects of supra- and subinhibitory
concentrations seem to be more important for
dosing regimens then PAE itself.
• A long PA SME/PME indicate that longer dosing
intervals may be used even for antibiotics, which
are dependent on the T>MIC for efficacy

More Related Content

What's hot

CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...
CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...
CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...
Eastern Pennsylvania Branch ASM
 
Emerging antibiotics in the ICU
Emerging antibiotics in the ICUEmerging antibiotics in the ICU
Emerging antibiotics in the ICU
Dr.Mahmoud Abbas
 
Role of Biomarkers Sepsis
Role of Biomarkers SepsisRole of Biomarkers Sepsis
Role of Biomarkers SepsisNireshan Naidoo
 
Xpert MTB RIF
Xpert MTB RIFXpert MTB RIF
Xpert MTB RIF
Dr. Rajat Prakash
 
Line probe assay 26 7-15
Line probe assay 26 7-15Line probe assay 26 7-15
Line probe assay 26 7-15
Yahya Noori, Ph.D
 
pk pd of antibiotics.pptx
pk pd of antibiotics.pptxpk pd of antibiotics.pptx
pk pd of antibiotics.pptx
PathKind Labs
 
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MDCarbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Society for Microbiology and Infection care
 
Smart therapy
Smart therapySmart therapy
Smart therapy
Khairul Jessy
 
Drug resistant gram - ve bacteria by Dr.T.V.Rao MD
Drug resistant gram - ve bacteria by Dr.T.V.Rao MDDrug resistant gram - ve bacteria by Dr.T.V.Rao MD
Drug resistant gram - ve bacteria by Dr.T.V.Rao MD
Society for Microbiology and Infection care
 
Molecular diagnosis in tuberculosis
Molecular diagnosis in tuberculosisMolecular diagnosis in tuberculosis
Molecular diagnosis in tuberculosis
Dr. Kanwal Deep Singh Lyall
 
Extended Spectrum Beta Lactamases Esbl
Extended Spectrum Beta Lactamases EsblExtended Spectrum Beta Lactamases Esbl
Extended Spectrum Beta Lactamases Esbl
Temujin Chavez
 
recent advances in Antitubercular vaccines
recent advances in Antitubercular vaccinesrecent advances in Antitubercular vaccines
recent advances in Antitubercular vaccines
priyanka527
 
Best Practice for Colistin Susceptibility Testing: Methods and Evidence (Mini...
Best Practice for Colistin Susceptibility Testing: Methods and Evidence (Mini...Best Practice for Colistin Susceptibility Testing: Methods and Evidence (Mini...
Best Practice for Colistin Susceptibility Testing: Methods and Evidence (Mini...
Abdullatif Al-Rashed
 
CBNAAT
CBNAATCBNAAT
CBNAAT
Ankur Gupta
 
Advanced diagnostics of tuberculosis 21 3-15
Advanced diagnostics of tuberculosis 21 3-15Advanced diagnostics of tuberculosis 21 3-15
Advanced diagnostics of tuberculosis 21 3-15
Yahya Noori, Ph.D
 
Treating Infectious Illness in the ICU
Treating Infectious Illness in the ICUTreating Infectious Illness in the ICU
Treating Infectious Illness in the ICUAndrew Ferguson
 
HOSPITAL ANTIBIOGRAMS principles interpretation and documentation
HOSPITAL ANTIBIOGRAMS principles  interpretation and documentationHOSPITAL ANTIBIOGRAMS principles  interpretation and documentation
HOSPITAL ANTIBIOGRAMS principles interpretation and documentation
Society for Microbiology and Infection care
 

What's hot (20)

CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...
CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...
CLSI Antimicrobial Susceptibility Update - Janet Hindler - November Symposium...
 
Emerging antibiotics in the ICU
Emerging antibiotics in the ICUEmerging antibiotics in the ICU
Emerging antibiotics in the ICU
 
Role of Biomarkers Sepsis
Role of Biomarkers SepsisRole of Biomarkers Sepsis
Role of Biomarkers Sepsis
 
Xpert MTB RIF
Xpert MTB RIFXpert MTB RIF
Xpert MTB RIF
 
Line probe assay 26 7-15
Line probe assay 26 7-15Line probe assay 26 7-15
Line probe assay 26 7-15
 
pk pd of antibiotics.pptx
pk pd of antibiotics.pptxpk pd of antibiotics.pptx
pk pd of antibiotics.pptx
 
COLISTIN
COLISTINCOLISTIN
COLISTIN
 
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MDCarbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MD
 
Smart therapy
Smart therapySmart therapy
Smart therapy
 
Drug resistant gram - ve bacteria by Dr.T.V.Rao MD
Drug resistant gram - ve bacteria by Dr.T.V.Rao MDDrug resistant gram - ve bacteria by Dr.T.V.Rao MD
Drug resistant gram - ve bacteria by Dr.T.V.Rao MD
 
Molecular diagnosis in tuberculosis
Molecular diagnosis in tuberculosisMolecular diagnosis in tuberculosis
Molecular diagnosis in tuberculosis
 
Tb newer diagnostics
Tb newer diagnosticsTb newer diagnostics
Tb newer diagnostics
 
Extended Spectrum Beta Lactamases Esbl
Extended Spectrum Beta Lactamases EsblExtended Spectrum Beta Lactamases Esbl
Extended Spectrum Beta Lactamases Esbl
 
recent advances in Antitubercular vaccines
recent advances in Antitubercular vaccinesrecent advances in Antitubercular vaccines
recent advances in Antitubercular vaccines
 
1 azim
1 azim1 azim
1 azim
 
Best Practice for Colistin Susceptibility Testing: Methods and Evidence (Mini...
Best Practice for Colistin Susceptibility Testing: Methods and Evidence (Mini...Best Practice for Colistin Susceptibility Testing: Methods and Evidence (Mini...
Best Practice for Colistin Susceptibility Testing: Methods and Evidence (Mini...
 
CBNAAT
CBNAATCBNAAT
CBNAAT
 
Advanced diagnostics of tuberculosis 21 3-15
Advanced diagnostics of tuberculosis 21 3-15Advanced diagnostics of tuberculosis 21 3-15
Advanced diagnostics of tuberculosis 21 3-15
 
Treating Infectious Illness in the ICU
Treating Infectious Illness in the ICUTreating Infectious Illness in the ICU
Treating Infectious Illness in the ICU
 
HOSPITAL ANTIBIOGRAMS principles interpretation and documentation
HOSPITAL ANTIBIOGRAMS principles  interpretation and documentationHOSPITAL ANTIBIOGRAMS principles  interpretation and documentation
HOSPITAL ANTIBIOGRAMS principles interpretation and documentation
 

Viewers also liked

Applying computational models for transporters to predict toxicity
Applying computational models for transporters to predict toxicityApplying computational models for transporters to predict toxicity
Applying computational models for transporters to predict toxicity
Sean Ekins
 
Quinolones | drug develoupment | mechanism of action | future
Quinolones | drug develoupment | mechanism of action | futureQuinolones | drug develoupment | mechanism of action | future
Quinolones | drug develoupment | mechanism of action | future
Arun Geetha Viswanathan
 
Quinolones
QuinolonesQuinolones
Quinolones
Zulcaif Ahmad
 
fluoroquinolones
 fluoroquinolones fluoroquinolones
fluoroquinolonesUmair hanif
 
Post antibiotic effect 2
Post antibiotic effect 2Post antibiotic effect 2
Post antibiotic effect 2
Gilang Rizki Al Farizi
 
General principles of antimicrobial therapy
General principles of antimicrobial therapyGeneral principles of antimicrobial therapy
General principles of antimicrobial therapy
Abialbon Paul
 
Antimicrobial susceptibility test and assay bls 209
Antimicrobial susceptibility test and assay bls 209Antimicrobial susceptibility test and assay bls 209
Antimicrobial susceptibility test and assay bls 209Bruno Mmassy
 
Tavanic levofloxacin
Tavanic levofloxacinTavanic levofloxacin
Tavanic levofloxacin
Ahmed Elrheem
 
Levoflox (Levofloxacin Tablets)
Levoflox (Levofloxacin Tablets)Levoflox (Levofloxacin Tablets)
Levoflox (Levofloxacin Tablets)
Clearsky Pharmacy
 
Fluoroquinolones
FluoroquinolonesFluoroquinolones
Fluoroquinolones
s_sadiya
 
Fluoroquinolones
FluoroquinolonesFluoroquinolones
Fluoroquinolonesshabeel pn
 
Pharmacology of Quinolones ppt satya
Pharmacology of Quinolones ppt   satyaPharmacology of Quinolones ppt   satya
Pharmacology of Quinolones ppt satya
sathyanarayanan varadarajan
 
Quinoline
QuinolineQuinoline
Quinoline
ridoyontor
 
Basic principles of antimicrobial therapy
Basic principles of  antimicrobial therapy Basic principles of  antimicrobial therapy
Basic principles of antimicrobial therapy
Javed Iqbal
 
Antibiotic resistance
Antibiotic resistance Antibiotic resistance
Antibiotic resistance
Naser Tadvi
 

Viewers also liked (18)

Applying computational models for transporters to predict toxicity
Applying computational models for transporters to predict toxicityApplying computational models for transporters to predict toxicity
Applying computational models for transporters to predict toxicity
 
Quinolones | drug develoupment | mechanism of action | future
Quinolones | drug develoupment | mechanism of action | futureQuinolones | drug develoupment | mechanism of action | future
Quinolones | drug develoupment | mechanism of action | future
 
Quinolones
QuinolonesQuinolones
Quinolones
 
Quinolones
QuinolonesQuinolones
Quinolones
 
Quinolones
QuinolonesQuinolones
Quinolones
 
fluoroquinolones
 fluoroquinolones fluoroquinolones
fluoroquinolones
 
Post antibiotic effect 2
Post antibiotic effect 2Post antibiotic effect 2
Post antibiotic effect 2
 
General principles of antimicrobial therapy
General principles of antimicrobial therapyGeneral principles of antimicrobial therapy
General principles of antimicrobial therapy
 
Antimicrobial susceptibility test and assay bls 209
Antimicrobial susceptibility test and assay bls 209Antimicrobial susceptibility test and assay bls 209
Antimicrobial susceptibility test and assay bls 209
 
Tavanic levofloxacin
Tavanic levofloxacinTavanic levofloxacin
Tavanic levofloxacin
 
Levoflox (Levofloxacin Tablets)
Levoflox (Levofloxacin Tablets)Levoflox (Levofloxacin Tablets)
Levoflox (Levofloxacin Tablets)
 
Fluoroquinolones
FluoroquinolonesFluoroquinolones
Fluoroquinolones
 
Fluoroquinolones
FluoroquinolonesFluoroquinolones
Fluoroquinolones
 
Pharmacology of Quinolones ppt satya
Pharmacology of Quinolones ppt   satyaPharmacology of Quinolones ppt   satya
Pharmacology of Quinolones ppt satya
 
Quinoline
QuinolineQuinoline
Quinoline
 
Basic principles of antimicrobial therapy
Basic principles of  antimicrobial therapy Basic principles of  antimicrobial therapy
Basic principles of antimicrobial therapy
 
Levofloxacin
LevofloxacinLevofloxacin
Levofloxacin
 
Antibiotic resistance
Antibiotic resistance Antibiotic resistance
Antibiotic resistance
 

Similar to Post antibiotic-sub-mic-effects

CAP.pptx
CAP.pptxCAP.pptx
Managment of Resistant Gram Negative Infections
Managment of Resistant Gram Negative InfectionsManagment of Resistant Gram Negative Infections
Managment of Resistant Gram Negative Infections
Yazan Kherallah
 
Managment of Resistant Gram Negative Infections
Managment of Resistant Gram Negative InfectionsManagment of Resistant Gram Negative Infections
Managment of Resistant Gram Negative Infections
Yazan Kherallah
 
Lab Presentation 8.1.16
Lab Presentation 8.1.16Lab Presentation 8.1.16
Lab Presentation 8.1.16Declan Feery
 
Antibiotics in surgery Dr Nesar Ahmad, AKTC, AMU
Antibiotics in surgery  Dr Nesar Ahmad, AKTC, AMUAntibiotics in surgery  Dr Nesar Ahmad, AKTC, AMU
Antibiotics in surgery Dr Nesar Ahmad, AKTC, AMU
Student
 
NewantibioticdevelopmentsforVAP_MNiederman_6JunFINAL (1).PPT
NewantibioticdevelopmentsforVAP_MNiederman_6JunFINAL (1).PPTNewantibioticdevelopmentsforVAP_MNiederman_6JunFINAL (1).PPT
NewantibioticdevelopmentsforVAP_MNiederman_6JunFINAL (1).PPT
biruktesfaye27
 
biomarker in sepsis.pptx
biomarker in sepsis.pptxbiomarker in sepsis.pptx
biomarker in sepsis.pptx
Dr. ZAHID IQBAL MIR
 
Cefditoren pivoxil: a new antibiotic for the treatment of respiratory infections
Cefditoren pivoxil:a new antibiotic for the treatment of respiratory infectionsCefditoren pivoxil:a new antibiotic for the treatment of respiratory infections
Cefditoren pivoxil: a new antibiotic for the treatment of respiratory infections
Jordi Roig
 
Neonatal sepsis 2
Neonatal sepsis 2Neonatal sepsis 2
Neonatal sepsis 2
Asim Ali
 
Clinical features,diagnosis and treatment of tuberculosis
Clinical features,diagnosis and treatment of tuberculosisClinical features,diagnosis and treatment of tuberculosis
Clinical features,diagnosis and treatment of tuberculosis
docpiash
 
Antbiotic Strategy in CAP
Antbiotic Strategy in CAPAntbiotic Strategy in CAP
Antbiotic Strategy in CAPGamal Agmy
 
Dr Mark Alderson @ MRF's Meningitis and Septicaemia 2019
Dr Mark Alderson @ MRF's Meningitis and Septicaemia 2019Dr Mark Alderson @ MRF's Meningitis and Septicaemia 2019
Dr Mark Alderson @ MRF's Meningitis and Septicaemia 2019
Meningitis Research Foundation
 
Refractory Idiopathic Thrombocytopenic Purpura
Refractory Idiopathic Thrombocytopenic PurpuraRefractory Idiopathic Thrombocytopenic Purpura
Refractory Idiopathic Thrombocytopenic Purpura
Mohammad Metwally
 
Peritonitis
PeritonitisPeritonitis
Antibiotics in surgery DR. SHILULI
Antibiotics in surgery   DR. SHILULIAntibiotics in surgery   DR. SHILULI
Antibiotics in surgery DR. SHILULI
Brian Shiluli
 
Diagnosis & management of tb in RNTCP
Diagnosis & management of tb in RNTCPDiagnosis & management of tb in RNTCP
Diagnosis & management of tb in RNTCPnavinthakkar
 
Copia de aminoglicosidos en uci
Copia de aminoglicosidos en uciCopia de aminoglicosidos en uci
Copia de aminoglicosidos en uciResidentes1hun
 
29 nov pct guided antibiotic use
29 nov pct guided antibiotic use29 nov pct guided antibiotic use
29 nov pct guided antibiotic use
PathKind Labs
 

Similar to Post antibiotic-sub-mic-effects (20)

CAP.pptx
CAP.pptxCAP.pptx
CAP.pptx
 
Managment of Resistant Gram Negative Infections
Managment of Resistant Gram Negative InfectionsManagment of Resistant Gram Negative Infections
Managment of Resistant Gram Negative Infections
 
Managment of Resistant Gram Negative Infections
Managment of Resistant Gram Negative InfectionsManagment of Resistant Gram Negative Infections
Managment of Resistant Gram Negative Infections
 
Lab Presentation 8.1.16
Lab Presentation 8.1.16Lab Presentation 8.1.16
Lab Presentation 8.1.16
 
Antibiotics in surgery Dr Nesar Ahmad, AKTC, AMU
Antibiotics in surgery  Dr Nesar Ahmad, AKTC, AMUAntibiotics in surgery  Dr Nesar Ahmad, AKTC, AMU
Antibiotics in surgery Dr Nesar Ahmad, AKTC, AMU
 
NewantibioticdevelopmentsforVAP_MNiederman_6JunFINAL (1).PPT
NewantibioticdevelopmentsforVAP_MNiederman_6JunFINAL (1).PPTNewantibioticdevelopmentsforVAP_MNiederman_6JunFINAL (1).PPT
NewantibioticdevelopmentsforVAP_MNiederman_6JunFINAL (1).PPT
 
biomarker in sepsis.pptx
biomarker in sepsis.pptxbiomarker in sepsis.pptx
biomarker in sepsis.pptx
 
Cefditoren pivoxil: a new antibiotic for the treatment of respiratory infections
Cefditoren pivoxil:a new antibiotic for the treatment of respiratory infectionsCefditoren pivoxil:a new antibiotic for the treatment of respiratory infections
Cefditoren pivoxil: a new antibiotic for the treatment of respiratory infections
 
Neonatal sepsis 2
Neonatal sepsis 2Neonatal sepsis 2
Neonatal sepsis 2
 
Clinical features,diagnosis and treatment of tuberculosis
Clinical features,diagnosis and treatment of tuberculosisClinical features,diagnosis and treatment of tuberculosis
Clinical features,diagnosis and treatment of tuberculosis
 
Antbiotic Strategy in CAP
Antbiotic Strategy in CAPAntbiotic Strategy in CAP
Antbiotic Strategy in CAP
 
Dr Mark Alderson @ MRF's Meningitis and Septicaemia 2019
Dr Mark Alderson @ MRF's Meningitis and Septicaemia 2019Dr Mark Alderson @ MRF's Meningitis and Septicaemia 2019
Dr Mark Alderson @ MRF's Meningitis and Septicaemia 2019
 
Refractory Idiopathic Thrombocytopenic Purpura
Refractory Idiopathic Thrombocytopenic PurpuraRefractory Idiopathic Thrombocytopenic Purpura
Refractory Idiopathic Thrombocytopenic Purpura
 
Peritonitis
PeritonitisPeritonitis
Peritonitis
 
Antibiotics in surgery DR. SHILULI
Antibiotics in surgery   DR. SHILULIAntibiotics in surgery   DR. SHILULI
Antibiotics in surgery DR. SHILULI
 
Antibiotics 1
Antibiotics 1Antibiotics 1
Antibiotics 1
 
Diagnosis & management of tb in RNTCP
Diagnosis & management of tb in RNTCPDiagnosis & management of tb in RNTCP
Diagnosis & management of tb in RNTCP
 
Copia de aminoglicosidos en uci
Copia de aminoglicosidos en uciCopia de aminoglicosidos en uci
Copia de aminoglicosidos en uci
 
29 nov pct guided antibiotic use
29 nov pct guided antibiotic use29 nov pct guided antibiotic use
29 nov pct guided antibiotic use
 
Lab diag. tb
Lab diag. tbLab diag. tb
Lab diag. tb
 

Recently uploaded

Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
Wasim Ak
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Jisc
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Atul Kumar Singh
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
Digital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion DesignsDigital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion Designs
chanes7
 
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama UniversityNatural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Akanksha trivedi rama nursing college kanpur.
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 
Chapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdfChapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdf
Kartik Tiwari
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
The French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free downloadThe French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free download
Vivekanand Anglo Vedic Academy
 
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdfMASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
goswamiyash170123
 

Recently uploaded (20)

Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
Digital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion DesignsDigital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion Designs
 
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama UniversityNatural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 
Chapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdfChapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdf
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
The French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free downloadThe French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free download
 
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdfMASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
 

Post antibiotic-sub-mic-effects

  • 1. The postantibiotic and sub-MIC The postantibiotic and sub-MIC effects in vitro and in vivo effects in vitro and in vivo Inga Odenholt, MD., Ph.D. Department of Infectious Diseases University hospital Malmö Sweden
  • 2. The postantibiotic effect in vitro The postantibiotic effect in vitro
  • 3. Postantibiotic effect; Postantibiotic effect; PAE in vitro PAE in vitro Definition: • Suppression of bacterial growth after short exposure of organisms to antibiotics PAE=T-C T= The time required for the exposed culture to increase one log10 above the count observed immediately after drug removal C= The corresponding time for the unexposed control
  • 4. Postantibiotic effect 9 8 7 log10 cfu/mL 2.3 h Control 6 PAE 5 4 3 0 2 4 6 8 10 12 h Odenholt et al. SJID, 1988
  • 5. Postantibiotic effect Postantibiotic effect in vitro in vitro The PAE is dependent on: • Type of antibiotic • Type of bacterial species • Concentration of the antibiotic • Duration of exposure • Size of the inoculum • Growth phase of the organism
  • 6. PAE against Gram-positive bacteria Antibiotics • Penicillins • Cephalosporins • Carbapenems • Quinolones • Proteinsythesis inhibitors hours 1-2 1-2 1-2 1-3 3-5
  • 7. PAE against Gram-negative bacteria PAE against Gram-negative bacteria • • • • • • Antibiotics Penicillins Cephalosporins Carbapenems Quinolones Proteinsythesis inhibitors Aminoglycosides hours 0 0 (1) 1-3 3-8 2-4
  • 8. PAE against P. aeruginosa PAE against P. aeruginosa • • • • • Antibiotics Penicillins Cephalosporins Carbapenems Quinolones Aminoglycosides hours 0 0 1-2 1-2 2-3
  • 9. The PAE at different concentrations against E. coli 8 7 6 hours 5 Rifampicin 4 Tetracykline Cefamandole 3 2 1 0 0,5 1 2 4 xMIC 8 16 32 Craig & Gudmundsson, 1991
  • 10. PAE at different exposure times against S. aureus 6 5 PAE (h) 4 Penicillin Erythromycin 3 2 1 0 0 2 4 6 8 10 12hours
  • 11. Effect on inoculum size on the PAE 120 100 Min 80 10 9 cfu/mL 10 7 cfu/mL 60 10 5 cfu/mL 10 3 cfu/mL 40 20 0 1 Ciprofloxacin 2 Tobramycin
  • 12. PAE in vitro PAE in vitro Methods Methods 1. Viable counts Methodological pitfalls • may overestimate killing • negative PAEs are common with ß-lactams and gram-negatives due to forming of filaments • similar inocula of the control and the preexposed culture are desirable
  • 13. Postantibiotic effect 9 8 7 log10 cfu/mL 2.3 h Control 6 PAE 5 4 3 0 2 4 6 8 10 12 h Odenholt et al. SJID, 1988
  • 14. PAE in vitro PAE in vitro Methods Methods 2. Optical density Methodological pitfalls • killing cannot be measured due to a detection limit of 106 cfu/ml • control curves at different inocula and viable counts after drug removal are necessary to be performed to ensure that PAE culture and control are at the same inoculum
  • 15. PAE in vitro PAE in vitro Methods Methods 3. ATP measurement Methodological pitfalls • bactericidal activity is underestimated due to dead but intact (not lysed) bacteria still containing intracellular ATP • PAE is overestimated due to falsely elevated ATP content
  • 16. PAE measured with ATP -7 log10 M bacterial ATP -8 -9 Control PAE Dilution -10 -11 0 1 2 3 4 5 6 7 8 9 h
  • 17. PAE in vitro PAE in vitro Methods Methods Morphology 4. • Phase contrast microscopy – the time it takes for the bacteria to revert to 90% bacilli • Ultrastructural changes - the changes in structure correlates well with the PAE measured with viable counting 5. 3H-thymidine incorporation -correlates well with the PAE measured with viable counting
  • 18. Control related effective Control related effective regrowth time (CERT) regrowth time (CERT)
  • 19. CERT CERT • Definition CERT=T-C T=the time required for resumption of logarithmic growth and increase of one log10 to occur over the preexposed inoculum of the test tube
  • 20. Calculation of CERT with bioluminescence 3 1.3 h 2 ATP log10 M 6h 1 PAE=4,7 h Control PAE 0 -1 -2 h -2 -1 0 1 2 3 4 5 6 7
  • 21. Calculation of CERT using viable counts 3 1.6 h 2 log10 cfu/mL 1 0 PAE=-0.3 h Control PAE -1 1.3 h -2 -3 -4 -2 -1 0 1 2 3 4 5 6 7 h
  • 22. The postantibiotic effect in vivo The postantibiotic effect in vivo
  • 23. Postantibiotic effect in vivo Postantibiotic effect in vivo Definition PAE= T-C-M • T= the time required for the counts of cfu in thighs of treated mice to increase one log10 above the count closest to but not less than the time M • C= the time required for the counts of cfu in thighs of untreated mice to increase one log10 above the count at time zero • M= the time serum concentration exceeds the MIC
  • 24. The postantibiotic effect of gentamicin against K. pneumoniae in vivo 10 9 8 log10 cfu/mL 7 6 5 4 Control PAE 3 T>MIC 2 1 0 -2 0 2 4 6 8 10 12 Fantin et al. JAC, 1990 14 h
  • 25. PAE in vivo PAE in vivo • Observed in several animal models • In vitro data are predictive of in vivo results except that in vivo PAE are usually longer due to the effect of sub-MICs and/or the effect of neutrophils • The major unexplained discordant results are for ß-lactams and streptococci
  • 26. PAE in vivo PAE in vivo Animal models Animal models •Thigh infections in mice •Pneumonia model in mice •Infected treads in mice •Infected tissue cages in rabbits •Meningitis model in rabbits •Endocarditis model in rats
  • 27. Mechanisms of PAE Mechanisms of PAE • β-lactam antibiotics. At least for S. pyogenes and penicillin it has been shown that PAE stands for the time it takes for the bacteria to resynthesize new PBPs
  • 28. Mechanisms of PAE Mechanisms of PAE • Erythromycin and clarithromycin: 50S ribosomal subunits were reduced during 90 min and protein synthesis during 4 h (PAE) due to prolonged binding of the antibiotics to 50S.
  • 29. Mechanisms of PAE Mechanisms of PAE • Aminoglycosides: Binding of sublethal amounts of drug enough to disrupt DNA, RNA and protein synthesis. The time it takes to resynthesize these proteins. With a half-life of >2.5 h, the PAE disappears, reflecting a sufficient time for the repair mechanism to be restored.
  • 30. The postantibiotic sub-MIC The postantibiotic sub-MIC effect in vitro effect in vitro
  • 31. Postantibiotic sub-MIC Postantibiotic sub-MIC effect; PA SME effect; PA SME Definition • The effect of subinhibitory antibiotic concentrations on bacteria previously exposed to suprainhibitory concentrations PA SME= TPA-C • TPA=the time it takes for the cultures previously exposed to antibiotics and thereafter to sub-MICs to increase by one log10 above the counts observed immediately after washing. • C=corresponding time for the unexposed control
  • 32. PA SME of telithromycin against H. influenzae 10 9 8 log10 cfu/mL 7 6 5 PAE 0.1xMIC 4 0.2xMIC 0.3xMIC Control 3 2 1 0 3 6 9 12 15 18 21 24 h
  • 33. The postantibiotic sub-MIC The postantibiotic sub-MIC effect in vivo effect in vivo
  • 34. PAE PASME) in vivo of amikacin against K. PAE (( PASME) in vivo of amikacin against K. pneumoniae in a thigh-infection model in pneumoniae in a thigh-infection model in mice mice • Normal mice (half-life 19 min) PAE 5.5 h • Uremic mice (half-life 98 min) 14.6 h
  • 35. The PAE and PA SME of piperacillin against S. aureus in vivo 9,00 8,50 8,00 log10 cfu/mL 7,50 7,00 Control PAE PA SME 6,50 6,00 5,50 Penicillinase 5,00 4,50 T>MIC 4,00 h -2 0 2 4 6 8 10 Oshida et al. JAC, 1990
  • 37. Post-MIC effect; PME Post-MIC effect; PME Definition • The effect of sub-MICs on bacteria previously exposed to a constant decreasing antibiotic concentration PME=Tpme-C • Tpme= The time for the counts in cfu of the exposed culture to increase one log10 above the count observed at the MIC level • C= the time for an unexposed control to increase one log10
  • 38. The post-MIC effect of benzylpenicillin against S. pneumoniae (PcR) 10 9 8 log10 cfu/mL 7 MIC 10mg/l 100 mg/l Control 6 5 4 PME at 10 mg/l 12.9-2.3= 10.6 3 PME at 100 mg/l 7.5-2.3= 5.2 2 1 0 2 4 MIC 6 8 10 12 14 16 18 20 22 24 h
  • 39. Mechanism of PA SME? Mechanism of PA SME? • The PAE of ß-lactam antibiotics seems to represent the time necessary to synthesize new PBPs. When bacteria in the PA-phase are exposed to sub-MICs, most PBPs are still inactivated and only a small amount of the drug is needed to prolong the inhibition of cell multiplication until a critical number of free PBPs are once more available
  • 41. Postantibiotic leucocyte Postantibiotic leucocyte enhancement; PALE enhancement; PALE • Bacteria pretreated with antibiotics for a brief period of time show increased susceptibility to intracellular killing and phagocytosis • In general, antibiotics that produce the longest PAEs exhibit maximal PALEs
  • 43. The SME of P&G kinolon against S. pneumoniae 9 8 log10 cfu/mL 7 6 Control 0.1xMIC 0.2xMIC 0.3xMIC 5 4 3 2 h 0 3 6 9 12 15 18 21 24
  • 44. Sub-MIC effects; SME Sub-MIC effects; SME Definition • The effect of subinhibitory antibiotic concentrations on bacteria not previously exposed to suprainhibitory concentrations SME= Ts-C •Ts=the time it takes for the cultures exposed to sub-MICs to increase by one log10 above the counts observed immediately after washing •C=corresponding time for the unexposed control
  • 45. Sub-MIC effects Sub-MIC effects • The minimum antibiotic concentrations that produces a structural change in bacteria seen by light or electron microscopy • The minimum antibiotic concentration that produces a one log10 decrease in the bacterial population compared to the control • Loss or change of bacterial toxins
  • 46. Sub-MIC effects Sub-MIC effects • Loss of surface antigens resulting in decreased adhesion • Increased rates of phagocytic ingestion and killing • Increased chemotaxsis and opsonization
  • 47. Mechanism of sub-MIC Mechanism of sub-MIC effects effects • SME probably tests the distribution of antibiotic susceptibility in the bacterial population, in which there are subpopulations that are inhibited by concentrations less than the MIC. The SME would therefore represent the time it takes for the population with the higher MIC to become dominant
  • 48. Implications Implications • The combined effects of supra- and subinhibitory concentrations seem to be more important for dosing regimens then PAE itself. • A long PA SME/PME indicate that longer dosing intervals may be used even for antibiotics, which are dependent on the T>MIC for efficacy